ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
COL8A1 as a pro-inflammatory mediator bridges immune evasion and therapy resistance in glioma
Provisionally accepted
Jiachong Wang1
Jiale LI1Jun Peng1Chunyuan Zhang2
Zigui Chen1*Changfeng Miao3*
Chunhai Tang4*
Qisheng Luo2*- 1Department of neurosurgery, Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou, China
- 2Youjiang Medical University for Nationalities, Baise, China
- 3Hunan Provincial People's Hospital, Changsha, China
- 4The Second Affiliated Hospital of Guangxi Medical University, Nanning, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Glioma remains the most aggressive and therapy-resistant brain tumor, with a highly immunosuppressive tumor microenvironment. The role of inflammatory signaling in glioma progression and treatment response is poorly understood. Methods: We performed single-cell RNA sequencing (scRNA-seq) analysis on 93,027 cells from 18 samples. Inflammation-related genes were identified using hdWGCNA and AUCell scoring. Multiple bulk RNA-seq and microarray datasets were integrated for validation. Machine learning algorithms, including CoxBoost, LASSO, and Random Survival Forest, were used to identify prognostic genes. Immune infiltration, immunotherapy response, and mutational landscape were analyzed using established computational tools. Findings: COL8A1 was found to be a significant prognostic gene within a highly linked gene module connected to inflammation. Astrocytes, OPCs, and cancerous cells all had high levels of COL8A1 expression. In several cohorts, low survival was linked to high COL8A1 expression. The suppression of tumor migration and proliferation by COL8A1 knockdown was validated by functional tests. Multiple immunotherapy determinants, inhibitory immunological checkpoints, and immune cell infiltration all showed high correlations with COL8A1 expression. Additionally, it accurately forecasted the immune checkpoint blockade response. Through mutational profiling, we identified distinct somatic mutation patterns distinguishing COL8A1-high from COL8A1-low cancers. Conclusion: By connecting tumor-intrinsic inflammation to immunological surveillance and treatment resistance, our study identified COL8A1 as a crucial inflammatory hub in glioma. In order to improve the results of immunotherapy for glioma, COL8A1 may be a useful therapeutic target and prognostic biomarker.
Keywords: Glioma, COL8A1, single-cell sequencing analysis, Immunotherapy, Inflammation
Received: 17 Oct 2025; Accepted: 28 Nov 2025.
Copyright: © 2025 Wang, LI, Peng, Zhang, Chen, Miao, Tang and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Zigui Chen
Changfeng Miao
Chunhai Tang
Qisheng Luo
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.